Dicklerl

Dicloberl is a drug from the NSAID subgroup, α-toluic acid derivative.

The active element of a therapeutic agent is the substance Diclofenac Na. The drug has an intense anti-inflammatory effect, slowing down the processes of binding the components of PG. At the same time, it has analgesic, antipyretic and anti-edematous (in the case of tissue swelling during inflammation) activity. Also, the drug weakens the adhesive activity of platelets under the influence of ADP with collagen.

[1]

Indications Diclberella

It is used to treat such disorders:

• diseases of rheumatic origin (rheumatism, rheumatoid arthritis or osteoarthritis);
• ankylosing spondylitis ;
• gout;
• articular lesions of a dystrophic nature;
• pain arising in case of injury to soft tissue or ODA;
• myalgia or neuralgia;
• having primary dysmenorrhea.

Release form

The release of the medication is realized in the form of injection fluid, inside the ampoules with a capacity of 3 ml (corresponds to 75 mg). In a pack - 5 such ampoules. In addition, it is available in the form of enteric tablets of 50 mg. 50 or 100 pieces inside the cell packaging.

It is also produced in the form of capsules with prolonged activity (volume of 0.1 g), 10, 20 or 50 each in a blister plate. Also implemented in the form of rectal suppositories (50 mg volume), 5 or 10 pieces inside the blister.

Pharmacokinetics

After the intramuscular injection of a drug, plasma Cmax is noted after 10-20 minutes. When ingested, it is completely absorbed through the intestines; Cmax values inside the blood plasma are recorded after 1-16 hours (on average, after 2-3 hours).

After intestinal absorption, presystemic metabolic processes develop with the first intrahepatic passage. 35-70% of the active element is involved in the post-hepatic circulation.

With the introduction of the suppository into the rectum plasma level Cmax is observed after half an hour.

About 30% of the drug is involved in metabolic processes. The elimination of metabolic elements is implemented through the intestines. Non-active metabolites formed during hepatocyte hydroxylation and conjugation are eliminated through the kidneys.

The term half-life is 120 minutes and does not change in case of impaired hepatic or renal activity. Synthesis with blood protein - 99%.

Dosing and administration

The substance should be injected parenterally with a deep intramuscular injection into the area of the buttock muscle. For the day is usually used 1 ampoule, equal to 75 mg of the drug. In general, the daily dose of drugs should not exceed 0.15 g of the substance. If prolonged therapy is required, use Dicloberl’s rectal or oral forms.

Tablets are taken orally, together with food (to prevent irritant effects on the gastric mucosa), while drinking down with plain water. Tablets do not chew. Daily dosage, comprising 50-150 mg, divided into 2-3 use. To choose the duration of treatment should the doctor, personally.

Capsules are used 1 time per day (portion 0.1 g). If you need an increase in dosage, use the tablet form of drugs.

Suppositories should be deeply inserted into the rectum after the act of defecation. Selection of portions is carried out by the doctor personally, taking into account the intensity of the disease. Often the daily dosage varies in the range of 50-150 mg. It is necessary to introduce such portion in 2-3 applications.

Use Diclberella during pregnancy

Dikloberl can not be used for breastfeeding or pregnancy.

Contraindications

Among the contraindications:

• severe allergies to diclofenac (or other substances from the NSAID subcategory);
• gastrointestinal tract ulcer;
• peptic ulcer;
• bleeding in the gastrointestinal tract;
• hematopoietic disorder;
• AND.

Side effects Diclberella

Main adverse events:

• lesions affecting the work of the gastrointestinal tract: exacerbation of gastrointestinal pathologies, constipation, dyspepsia, nausea, diarrhea, loss of appetite, abdominal pain and vomiting. In addition, pancreatitis, glossitis, hepatic disorder, esophagitis, weak bleeding in the gastrointestinal tract. In people with diseases of the gastrointestinal tract may appear bleeding or perforation of existing ulcers. Bloody diarrhea or vomiting, and also a melena is individually observed;
• dysfunction of the central nervous system: severe fatigue, dizziness, taste changes, feeling of excitement, insomnia, headaches, convulsions and fear. In addition, there are disorders of sensitivity or vision, changes in sound perception, nightmarish dreams, a feeling of disorientation, tremor, confusion, depression, and stiff neck (aseptic meningitis);
• allergy symptoms: bullous or epidermal rash, burning in the injection area, itching, PET, abscess of a sterile nature or necrosis of the subcutaneous layers in the injection area, and in addition SJS, bronchial spasm, laryngeal swelling, tongue or face, and anaphylaxis;
• disorders of hematopoietic activity: leuko- or thrombocytopenia, agranulocytosis or anemia;
• problems with the work of the cardiovascular system: palpitations, increase or decrease in blood pressure and pain in the sternum;
• other: in the case of necrotizing fasciitis, a deterioration in the general condition may be observed; allergic vasculitis and pulmonitis are also possible.

Overdose

In case of overdose with medication, symptomatic measures should be taken. Headaches, a feeling of disorientation, loss of consciousness, dizziness, and myoclonic convulsions (in children) may occur; In addition, abdominal pain, vomiting, bleeding inside the gastrointestinal tract, liver or kidney disorders and nausea can occur.

Interactions with other drugs

The use of drugs with digoxin, phenytoin or lithium drugs increases the plasma values of the latter.

Combination with antihypertensive and diuretic substances leads to a weakening of their therapeutic effect.

The combination with potassium-sparing diuretic drugs causes an increase in blood parameters of potassium.

Dikloberl used with ACE inhibitors can lead to disorders of renal activity.

Use with GCS and other NSAIDs leads to a potentiation of negative effects on the gastrointestinal tract.

The use of the drug a day before or after the use of methotrexate causes an increase in the latter and potentiation of its toxicity.

The combination with antiplatelet agents requires medical supervision of the work of the circulatory system (although no interaction has yet been found).

Use together with cyclosporine potentiates its toxicity.

Drugs containing probenecid inhibit diclofenac excretion.

There are isolated data on changes in serum indicators of sugar in diabetics, requiring changes in the dosage of hypoglycemic drugs and insulin.

Storage conditions

Dikloberl must be kept in a dark place closed to small children. Temperature - within 25 ° С.

Shelf life

Dikloberl allowed to apply for a 36-month term from the date of sale of the drug.

Application for children

It is forbidden to prescribe medication to persons under the age of 15 years.

Analogs

Analogues of drugs are Naklofen, Almiral, Diklak with Ibuprofen, and besides this Argett Rapid, Ortofen, Bioran, Rapten with Voltaren, Feloran, Diclofenac and Olfen with Diklobr, and Ketarolak.

Reviews

Dikloberl receives good feedback from patients - helps quickly and effectively eliminate moderate pain. But keep in mind that the medicine in the form of injections is prohibited to use constantly. It is used only 1-fold, because it has an increased likelihood of developing negative symptoms (mainly gastric). The lack of effect is observed only occasionally, if the intensity of pain is assessed correctly. Allergy also occurs quite rarely.